Rockwell Medical Inc (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the …
In a research report published Friday, Brean Capital analyst Jonathan Aschoff maintained a Sell rating on Rockwell Medical Inc (NASDAQ:RMTI) with a $4.00 price target, …
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for …
In a research report sent to investors today, Oppenheimer analyst Ling Wang reiterated an Outperform rating on Rockwell Medical (NASDAQ:RMTI) with a $26 price …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff reiterated a Sell rating on Rockwell Medical (NASDAQ:RMTI) with a …
Oppenheimer analyst Ling Wang initiated Outperform rating on Rockwell Medical (NASDAQ:RMTI) with a $24 price target, which represents a potential upside of 152% …
After an eventful 2014, the Brean Capital team came together to pick 28 stocks within each of the firm’s four coverage verticals, Consumer, …
In a research report released today, Brean Capital analyst Jonathan Aschoff reiterated a Sell rating on Rockwell Medical (NASDAQ:RMTI) with a $4 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Sell rating on Rockwell Medical (NASDAQ:RMTI) with a price target …
In a research report published today, Brean Capital analyst Jonathan Aschoff reaffirmed a Sell rating on Rockwell Medical (NASDAQ:RMTI) with a $4.00 price target, which represents …
